🇺🇸 FDA
Pipeline program

Olumiant 4 mg film-coated tablets, Placebo of Olumiant 4mg

APHP180612

Phase 3 small_molecule active

Quick answer

Olumiant 4 mg film-coated tablets, Placebo of Olumiant 4mg for Dermatomyositis; Baricitinib in patients with relapsing or naïve dermatomyositis. is a Phase 3 program (small_molecule) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Pari Pharma GmbH
Indication
Dermatomyositis; Baricitinib in patients with relapsing or naïve dermatomyositis.
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials